Esperion Announces Proposed Public Offering
December 02 2021 - 5:00PM
Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today
announced that it intends to offer and sell, subject to market and
other conditions, shares of its common stock (or common stock
equivalents in lieu thereof) and warrants to purchase shares of
common stock in an underwritten public offering. The Company
expects to grant the underwriter a 30-day option to purchase
additional shares of its common stock and/or warrants to purchase
shares of its common stock at the public offering price, less the
underwriting discounts and commissions. All of the securities to be
sold in the offering are to be offered by Esperion.
H.C. Wainwright & Co. is acting as sole
book-running manager for the proposed public offering.
The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Esperion intends to use the net proceeds from
the offering to fund the ongoing commercialization efforts for
NEXLETOL and NEXLIZET, research and clinical development of current
or additional pipeline candidates, and general corporate
purposes.
The securities described above are being offered
by Esperion pursuant to a shelf registration statement on
Form S-3ASR (File No. 333-258397) that was previously filed
with the Securities and Exchange Commission (the “SEC”) on August
3, 2021 and which became effective upon filing. The securities may
be offered only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement.
A preliminary prospectus supplement and accompanying base
prospectus relating to, and describing the terms of, the offering
will be filed with the SEC and will be available on the SEC’s
website at www.sec.gov. Electronic copies of the preliminary
prospectus supplement and the accompanying base prospectus relating
to the offering, when available, may also be obtained by contacting
H.C. Wainwright & Co., LLC, at 430 Park Ave., New York, New
York 10022, by telephone at (212) 856-5711, or by email at
placements@hcwco.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy the securities in this
offering, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Esperion Therapeutics
Esperion is The Lipid Management Company. Our
goal is lipid management for everybody, that’s why we work hard to
make our medicines easy to get, easy to take and easy to have. We
discover, develop and commercialize innovative medicines and
combinations to lower cholesterol, especially for patients whose
needs aren’t being met by the status quo. Our entrepreneurial team
of industry leaders is inclusive, passionate and resourceful. For
more information, please visit www.esperion.com and follow us
on Twitter at www.twitter.com/EsperionInc.
Forward-Looking Statements
This press release contains forward-looking
statements that are made pursuant to the safe harbor provisions of
the federal securities laws, including, without limitation,
statements related to the terms, timing and completion of the
proposed public offering, the satisfaction of customary closing
conditions related to the proposed public offering and the intended
use of proceeds from the proposed public offering. Any express or
implied statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties that could cause Esperion's actual results to differ
significantly from those projected, including, without limitation,
market and other conditions, the impact of COVID-19 on our
business, clinical activities and results, supply chain, commercial
development and launch plans, and the risks detailed in Esperion's
filings with the Securities and Exchange Commission. All
forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary
statements. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Esperion disclaims
any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
Contact:
Corporate CommunicationsBen Church/Kaitlyn
Broscobchurch@esperion.com / kbrosco@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2024 to Jun 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2023 to Jun 2024